How Long Does Alzheimer's Treatment Last? Reviews, Antibody Therapy, and Planning Care in China

Alzheimer's disease generally requires continuing management, but that does not mean every medicine is prescribed indefinitely. Nor does completing a set of infusions finish the person's care. When families ask how long treatment takes, they may mean how soon a medicine can help, when it should be reviewed, whether it can eventually stop, or how long a visit to China should last. These questions need separate answers.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Diagnostic work takes time according to the information already available, appointment access, and whether other causes need investigation. Dose adjustment allows clinicians to assess tolerability. A treatment review considers symptoms and function. Long-term prescribing then depends on repeated decisions as the person's circumstances change.
A pause because of ARIA, a serious reaction, or another illness is different from a delayed appointment. Restarting may require clinical reassessment and imaging. The passage of a certain number of weeks cannot alone establish that treatment is ready to resume.
Treatment takes time beyond the appointment itself: transport, waiting, accompaniment, meals, and recovery from a tiring day all count. A theoretically possible schedule that repeatedly exhausts the patient or cannot be supported by the family deserves review. Coordinate medication visits, rehabilitation activities, and appointments for other conditions to reduce duplication and identify gaps.

Quick answer

Full guide

Current treatment cannot promise a cure. Decisions to continue should reflect daily function, tolerability, disease stage, practical demands, and the person's priorities. Tell the team what matters in ordinary life, such as taking part in meals, communicating with relatives, or retaining a familiar activity. These goals are more useful than an unexplained request to “extend the course.” NIA treatment information

There are several different clocks

Diagnostic work takes time according to the information already available, appointment access, and whether other causes need investigation. Dose adjustment allows clinicians to assess tolerability. A treatment review considers symptoms and function. Long-term prescribing then depends on repeated decisions as the person's circumstances change.

A visit that allows a memory consultation, imaging review, and prescription discussion may not also allow complete antibody eligibility assessment and treatment initiation. Conversely, taking a medicine for years does not necessarily require years of hospital attendance. Ask the Chinese center to identify what can be completed at home, what requires an in-person visit, and which decisions must wait for test results.

This distinction also helps when reading a quotation. A quoted assessment period is not a guaranteed time to diagnosis, and a booked infusion appointment does not establish eligibility. The medical sequence should be clear before the family commits to a fixed travel timetable.

The first weeks establish safe, reliable use

Donepezil is commonly started at a lower dose, with a possible increase after four to six weeks depending on the prescription and response. Galantamine also requires intervals between increases. These intervals are product-specific, not an instruction that every patient must reach the same dose as quickly as possible. Donepezil information, Galantamine information

Early follow-up should establish what was actually taken, alongside appetite, weight, sleep, falls, and other adverse changes. Several weeks of repeated missed doses may not constitute an adequate treatment trial. Persistent vomiting or fainting should not be endured merely to remain on an escalation calendar. The schedule needs to fit the patient rather than become a target in its own right.

Caregiving arrangements matter during this period. If different relatives administer treatment, agree on one way to record it. Let the clinician know if swallowing difficulties, an unfamiliar medicine name, or uncertainty about instructions has made reliable dosing difficult. Those obstacles may be solvable, but they need to be visible.

Oral symptom medicines do not share a fixed stopping date

Benefit may appear as retention of some abilities or less difficulty in particular aspects of care; it does not necessarily look like a return to an earlier level of memory. Continued decline is a reason to review the situation, but it cannot by itself show exactly what would have happened without treatment.

NICE advises against stopping a cholinesterase inhibitor solely because Alzheimer's disease has become more severe. Tolerability, continuing benefit, and overall care goals still matter. This recommendation should not be interpreted as a promise that every person must take the medicine for life. NICE NG97

For reviews, choose a few ordinary activities to observe consistently. Examples might include following a familiar cooking step or using a known telephone to contact a relative. Record changes in hearing, sleep, or intercurrent illness that could affect performance. Repeatedly quizzing a person every day can create distress without providing a reliable measure of long-term treatment effect.

Eighteen months is not an automatic endpoint for lecanemab

The principal CLARITY AD comparison assessed cognitive and functional changes at 18 months. This describes how the trial measured outcomes. It does not establish that every patient can stop treatment after 18 months or that a family will notice a response after a particular numbered dose. Original CLARITY AD study

The July 2026 US Leqembi label allows continuation of the starting regimen after 18 months or consideration of an intravenous or subcutaneous maintenance regimen. It also notes limited data on the long-term clinical benefit of transitioning to those maintenance schedules. Maintenance changes the ongoing administration plan; it does not imply that the underlying treatment goal has been permanently achieved. The Chinese treating team must explain the options under the applicable local labeling. 2026 Leqembi label

Before starting, families can ask how later reviews will address function, adverse events, attendance demands, and changing care preferences. A decision that was reasonable at initiation deserves reconsideration when circumstances change. That is part of treatment management, not evidence that the initial decision was necessarily mistaken.

Donanemab has a different stopping discussion

The cited US Kisunla label allows consideration of stopping when amyloid PET shows reduction of plaques to minimal levels. This is a drug-specific approach and should not be applied automatically to every anti-amyloid antibody. MRI used for safety surveillance and amyloid PET used in this stopping assessment have different purposes. Kisunla prescribing information

The 2025 appropriate use recommendations discuss follow-up PET and acknowledge gaps in knowledge about optimal duration and practical implementation. Their early dosing schedule was subsequently updated in labeling, so readers must separate the duration discussion from prescribing details that have changed. Donanemab appropriate use recommendations, Alzheimer's Association update notice

Reduced plaque burden does not mean that all disease processes have disappeared or that lost abilities have returned. Cognitive, functional, and safety follow-up remains relevant after a clinician decides to finish antibody dosing. Future reassessment or retreatment should not be advertised in advance as a routine annual “cleansing course.”

An interruption needs a reason and a restart decision

A pause because of ARIA, a serious reaction, or another illness is different from a delayed appointment. Restarting may require clinical reassessment and imaging. The passage of a certain number of weeks cannot alone establish that treatment is ready to resume.

If a scheduled scan has not been reviewed by the responsible clinician, contact the team about the next dose. Do not compress treatment intervals to fit flights or regard a larger dose as a substitute for missed administrations. Travel arrangements should accommodate the clinical decision rather than force it to fit a prepaid package.

Ask for the reason for any interruption to be documented. “Treatment paused” without the relevant symptoms, imaging findings, and follow-up plan gives a receiving hospital too little information. The next clinician needs to know whether a problem resolved, remains under investigation, or changed the longer-term treatment choice.

Missing one dose differs from restarting after a gap

Restart instructions vary by medicine. Donepezil interrupted for a week or longer, rivastigmine patches omitted for several days, and memantine missed for several days can require advice before resumption. Previous tolerance of a dose does not guarantee that returning to it directly is appropriate after an interruption. Donepezil guidance, Rivastigmine patch guidance, Memantine guidance

Before travelling to China, list generic names, strengths, formulations, and the quantity actually remaining. If a brand changes, have a pharmacist or physician check the ingredient and release formulation. Tell the receiving clinician the true length of any interruption. Showing an old prescription without mentioning that the medicine ran out can conceal a clinically important change.

Deprescribing can be a planned part of care

Persistent adverse effects, difficulty administering treatment, an inappropriate original indication, lack of identifiable continuing benefit, or a substantial change in care goals may prompt a discussion about reducing symptom medicines. Include the patient's expressed preferences as far as possible and the care partner's observations.

CCCDTD5 recommends gradual deprescribing of cognitive enhancers when appropriate, with monitoring and consideration of reintroduction if clinically meaningful deterioration appears related to cessation. Medicines that improved important neuropsychiatric symptoms require particular care when considering withdrawal. These principles are for clinician-guided decisions, not a universal family-managed taper. CCCDTD5 recommendations

A Cochrane review found that stopping cholinesterase inhibitors may worsen some cognitive or functional outcomes, while also identifying limitations in the evidence. It cannot supply one best stopping time for everyone. A planned withdrawal should specify what will be observed and when contact will occur; it should not become an accidental interruption after a prescription expires. Cochrane review

Plan the stay in China around continuity

An initial visit can focus on confirming the diagnosis and obtaining a workable plan. Starting an antibody also requires an answer to where later dosing and safety checks will happen. The September 2026 Chinese approval announcement for subcutaneous lecanemab initiation is relevant to future options, but it does not prove immediate local stock, permission to take it into every country, or an end to follow-up. Chinese approval announcement

Confirm the first appointment after returning home, image transfer arrangements, and prescribing responsibility with both teams before deciding how long the initial stay should be. If care cannot yet continue in the home country, establish what additional arrangements would be needed before departure. A universal number of days in China would be misleading because eligibility work, bookings, and clinical needs vary.

A sustainable schedule includes the caregiver

Treatment takes time beyond the appointment itself: transport, waiting, accompaniment, meals, and recovery from a tiring day all count. A theoretically possible schedule that repeatedly exhausts the patient or cannot be supported by the family deserves review. Coordinate medication visits, rehabilitation activities, and appointments for other conditions to reduce duplication and identify gaps.

Daily support changes with disease stage. Reminders, home safety measures, meaningful activities, and caregiver education do not cease to matter when one medication assessment ends. At each review, establish what is continuing, why it remains appropriate, how the next decision will be made, and which changes should prompt earlier contact. That produces a plan capable of adapting to the person rather than relying on a promised completion date. NIA continuing care guidance